Sage Faces Multiple Moments Of Truth For Zuranolone, GABA Modulation

Parkinson’s Data For NMDA Modulator Also On Tap Before Year’s End

Before pivotal depression data in 2021 attempt to redeem zuranolone after a failed Phase III study, the company will report Phase II results for next-gen GABA modulator SAGE-324 in essential tremor.

A man standing on top of a mountain as the sun sets
Sage may get a shot at redemption with zuranolone in depression • Source: Shutterstock

Three pivotal studies reading out in 2021 could redeem Sage Therapeutics, Inc.’s zuranolone (SAGE-217) following its failure in the acute treatment of major depressive disorder at the end of last year. Before then, however, Phase II results for its next-generation drug SAGE-324 in chronic treatment of essential tremor could reinforce the company’s confidence in its GABA-modulation approach to mood and movement disorders.

Three Phase III clinical trials of zuranolone are under way in two different major depressive disorder (MDD) settings and in postpartum depression (PPD) with results due next year. Top-line data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Neurological

More from Therapy Areas